审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向:肿瘤细胞免疫 经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.(当天修回) Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下) 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据) 22 Nov 2023 Submitting Author ** submitted manuscript.
偏重的研究方向:肿瘤 经验分享:各位大佬,请问这个拒稿意见是什么意思啊? Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.
目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?
60
审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向:肿瘤
经验分享:非常水……😌😌😌😌
58
这个投稿快一个月了,还一直在编辑手中,怎么办啊
12
审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:肿瘤细胞免疫
经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。
02 May 2024 Article accepted for publication.
29 Apr 2024
Submitting Author ** posted new comments in the Editor tab.(当天修回)
Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)
27 Apr 2024 Review of Review Editor 2 finalized.
23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.
12 Apr 2024 Interactive review forum activated automatically.
07 Apr 2024 Reviewer 2: Minor revision is required.
07 Mar 2024 Review of Reviewer 1 is finalized.
08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.
25 Nov 2023 Submitting Author ** resubmitted the manuscript.
23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)
22 Nov 2023 Submitting Author ** submitted manuscript.
12
偏重的研究方向:肿瘤
经验分享:各位大佬,请问这个拒稿意见是什么意思啊?
Reason:
Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.
19
审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:肿瘤;生信
经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!
11 Apr 2023 Article accepted for publication.
07 Apr 2023 Review of Review Editor 3 finalized.
01 Apr 2023 Review of Review Editor 4 finalized.
30 Mar 2023 Review of Review Editor 1 finalized.
17 Mar 2023 Interactive review forum activated.
07 Feb 2023 submitted manuscript
109
审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:肿瘤
经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!
献上我的投稿过程,供以后的朋友参考:
24 Jan 2024 Article accepted for publication.
08 Jan 2024 Review of Review Editor 1 finalized.
07 Jan 2024 Review of Review Editor 2 finalized.
03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.
29 Dec 2023 Interactive review forum activated.
11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript.
35
审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:肿瘤;罕见基因变异;案例报道
经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!
2022.12.14号,提交Manuscript,Initial Validation
2022.12.19号,Editorial Assignment 稿件分配编辑
2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立
2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应
2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内
2023.03.16,Interactive review交互评审
2023.03.24,提交第一轮审稿意见和修改稿
2023.03.28,Review Finalized
2023.04.07,accepted
2023.04.12,Author's Proof,要求两天内提交
2023.04.25,支付版面费,2020 USD,限期一个月
2023.04.28,在线发表。
95
偏重的研究方向:肿瘤;免疫治疗;生信
经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…
23
审稿速度:1.0
偏重的研究方向:诊断;肿瘤;临床
经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新
34